Green Cross, a Korean biopharmaceutical company, said Wednesday it presented the successful clinical trial results of a novel treatment for hepatitis B under development, GC1102, at a medical conference in Seoul last week.
The company highlighted the results of ongoing phase II clinical trials on its new drug at this year’s International Liver Transplantation Society meeting.
 |
Green Cross delivers a presentation at a symposium held on May 6 as part of this year’s International Liver Transplantation Society meeting, which took place at Coex in Seoul from May 4-7. (Green Cross) |
By utilizing immunoglobulins as its main treatment source, Green Cross’ new hepatitis B drug delivers improved therapeutic effects and usage safety compared to its conventional plasma-based counterparts.
So far, GC1120 has been shown to successfully prevent the recurrence of hepatitis B virus infections following liver transplantation among 29 Korean patients, Green Cross said. The clinical study will continue in the months ahead.
Given its fast-paced development trajectory, GC1120 is “highly likely to become the world’s first ever immunoglobulin-based hepatitis B drug,” said Green Cross’ senior managing director Park Dae-woo.
According to a 2015 report by the World Health Organization, there are roughly 240 million hepatitis B patients worldwide, many of whom are diagnosed with liver-related diseases and cancers, requiring a liver transplant.
By Sohn Ji-young (
jys@heraldcorp.com)
